Bird...After the Anchor debacle, Amarin was in financial duress and had to let half their reps go...Amarin then partnered with KOWA to provide more reps. Kowa had their own drug, Lovastatin, which they promoted to Docs, often without even mentioning Vascepa...This turned out to be an ill conceived deal and Amarin ended it as soon as they could.
This deal is still in the minds of Amarin's BOD and I doubt they would be in a rush to repeat anything like it.
Pfizer is not Kowa, but they have their own interests, which I am sure they will pursue diligently...IMO a BO, not a partnership, would be the preferable course.
Pfizer can well afford to buy Amarin and does not need to partner with it.
News 
Market Data 
Discover 
